For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221121:nRSU1012Ha&default-theme=true
RNS Number : 1012H IP Group PLC 21 November 2022
FOR RELEASE ON 21 November 2022
IP Group plc - Life sciences presentation postponed
Further to the announcement on 2 November, IP Group plc (LSE: IPO) ("IP Group"
or "the Company"), which develops world-changing science and technology
businesses across life sciences, technology and cleantech, notes that due to
circumstances beyond its control, the Company is postponing the investor
presentation titled 'Life Sciences: Changing Medicine' that was scheduled for
Wednesday 30 November 2022.
The Company apologises for any inconvenience this may cause and looks forward
to rescheduling as soon as practicable.
For more information, please contact:
IP Group plc www.ipgroupplc.com (http://www.ipgroupplc.com)
Liz Vaughan-Adams, Communications +44 (0) 20 7444 0050
+44 (0) 20 7444 0062/+44 (0) 7967 312125
Charlotte Street Partners
David Gaffney +44 (0) 7854 609998
Andrew Wilson +44 (0) 7810 636995
Notes for editors
About IP Group
IP Group develops world-changing science and technology businesses across life
sciences, technology and cleantech (through Kiko Ventures). The Group has a
strong track record of success, having been the founder investor in a number
of high-profile companies including Oxford Nanopore Technologies plc, and has
one of the most exciting portfolios of high-growth businesses in Europe. The
Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs
world-changing technologies emerging from the UK's leading universities and
research institutions. IP Group is listed on the Main Market of the London
Stock Exchange under the code IPO.
For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .
ENDS
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAPPGGGGUPPGCG